EUROPEAN
COMMISSION

Brussels, XXX
SANTE/10850/2017 ANNEX
(POOL/E4/2017/10850/10850-EN
ANNEX.doc)
[…](2017) XXX draft

ANNEX 1

ANNEX

to the

COMMISSION IMPLEMENTING REGULATION (EU) …/...

approving L(+) lactic acid as an existing active substance for use in biocidal products of product-types 2, 3 and 4

ANNEX

Common Name	IUPAC Name Identification Numbers	Minimum degree of purity of the active substance[1]	Date of approval	Expiry date of approval	Product type	Specific conditions
L(+) lactic acid	IUPAC Name: (S)-2-Hydroxypropanoic acid EC No: 201-196-2 CAS No: 79-33-4	≥ 955 g/kg (dry weight)	1 May 2019	30 April 2029	2	The authorisations of biocidal products are subject to the following condition: The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.
					3	The authorisations of biocidal products are subject to the following conditions: 1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance. 2) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to groundwater for products used in animal housings with release to manure.
					4	The authorisations of biocidal products are subject to the following conditions: 1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.

[1] The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

						2) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.